abstract |
Methods of treating, preventing and/or managing multiple myeloma are disclosed. nSpecific methods encompass the administration of an immunomodulatory compound, e.g., nlenalidomide or pomalidomide with an anti-CS1 antibody, e.g., elotuzumab in patients who nhave received autologous stem cell transplantation. |